IHH HEALTHCARE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.12 MYR | +0.49% |
|
+0.99% | +1.49% |
| Apr. 05 | IHH Healthcare Names CFO | MT |
| Apr. 05 | IHH Healthcare Berhad Appoints Dilip Kadambi as Group Chief Financial Officer | CI |
| Sales 2024 * | 22.1B 4.62B | Sales 2025 * | 23.64B 4.95B | Capitalization | 53.63B 11.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.73B 363M | Net income 2025 * | 1.92B 403M | EV / Sales 2024 * | 2.74 x |
| Net Debt 2024 * | 6.85B 1.43B | Net Debt 2025 * | 6.5B 1.36B | EV / Sales 2025 * | 2.54 x |
| P/E ratio 2024 * |
30.6
x | P/E ratio 2025 * |
27.9
x | Employees | 65,000 |
| Yield 2024 * |
1.32% | Yield 2025 * |
1.41% | Free-Float | 24.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on IHH Healthcare
More recommendations
| 1 week | +0.50% | ||
| Current month | +0.66% | ||
| 3 months | +2.18% | ||
| 6 months | +2.53% | ||
| Current year | +1.00% |
1 week
6.00
6.15
1 month
5.936.17
Current year
5.936.25
1 year
5.646.25
3 years
5.127.34
5 years
4.557.34
10 years
3.857.34
| Managers | Title | Age | Since |
|---|---|---|---|
Prem Kumar Nair
CEO | Chief Executive Officer | 64 | 23-09-30 |
Penelope Koh
IRC | Investor Relations Contact | - | - |
Ashok Pandit
PRN | Corporate Officer/Principal | 58 | 21-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mehmet Aydinlar
BRD | Director/Board Member | 67 | 12-01-23 |
| Chairman | 67 | 11-03-29 | |
| Director/Board Member | 64 | 20-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.05% | 2 M€ | -14.14% | ||
| 2.73% | 4 M€ | +6.85% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 6.12 | +0.49% | 3 874 900 |
| 24-04-18 | 6.09 | 0.00% | 3,481,700 |
| 24-04-17 | 6.09 | -0.16% | 5,294,500 |
| 24-04-16 | 6.1 | +1.16% | 3,682,200 |
| 24-04-15 | 6.03 | -0.99% | 4,625,700 |
End-of-day quote BURSA MALAYSIA, April 17, 2024
More quotes
IHH Healthcare Berhad is a Malaysia-based integrated healthcare provider. The Company's segments include Hospital and Healthcare, IMU Health, Labs, PLife REIT and Others. It operates its Hospital and Healthcare segment in Singapore, Malaysia, India, Greater China, Turkey and Europe and Southeast Asia. The IMU Health segment is engaged in providing educational services. The Labs segment provides diagnostic laboratory services. The PLife REIT segment is a real estate investment trust. Through its portfolio of brands, such as Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway, the Company offers its patients comprehensive and personalized care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging, and rehabilitation. It provides day-to-day healthcare services through outpatient treatment, routine check-ups, and vaccinations. Its secondary care comprises specialist consultation, local surgeries, and others.
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
6.09
MYR
Average target price
7.13
MYR
Spread / Average Target
+17.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.00% | 11.21B | |
| -21.49% | 16.01B | |
| +0.90% | 12.09B | |
| +7.06% | 10.45B | |
| +17.84% | 7.87B | |
| -4.75% | 7.45B | |
| +22.00% | 7.27B | |
| +3.81% | 6.63B | |
| +43.14% | 4.41B | |
| -1.16% | 4.42B |
- Stock Market
- Equities
- IHH Stock
